Diabetic peripheral neuropathy (DPN) is a common complication of diabetes, affecting approximately 50% of diabetic patients. It can lead to chronic pain, foot ulcers, and amputations, significantly impacting patients’ quality of life.
Despite extensive research, there are no mechanism-based treatments for DPN, and current treatments are often inadequate. However, recent advances in understanding the pathogenesis of DPN have led to the identification of new potential therapeutic targets and interventions.
As medical research advances, new approaches in the management of neuropathy continue to emerge. These innovative treatments aim to target the underlying causes of neuropathy and provide more effective and long-lasting relief for patients. In Recent times Benfotiamin & Alpha Lipoic Acid has been gaining attention in the treatment of Nerve disorders.
Benfotiamine is currently successfully used by thousands of physicians in the treatment of peripheral neuropathy. Benfotiamine is believed to work by restoring vitamin B1 levels in diabetics, alcoholics, the obese, and the elderly. These groups are prone to develop peripheral neuropathy in which vitamin B1 deficiency is often a factor. On a metabolic level, benfotiamine has been shown to block complication-causing pathways associated with diabetic polyneuropathy-including the polyol, AGE, PKC, and hexosamine pathways. It is extremely safe. There are no significant adverse effects associated with its use.
Alpha-lipoic acid is an antioxidant that plays a vital role in energy metabolism. It has been studied for its potential neuroprotective properties in neuropathy management. Alpha-lipoic acid has shown efficacy in reducing neuropathic pain and improving neuropathic symptoms, primarily in individuals with diabetic neuropathy. Its antioxidant effects may help reduce oxidative damage and promote nerve regeneration
To read more pls click below